DS
KLDO

David Shaw’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

David Shaw’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-18,827
Closed -$45K – 6189
2021
Q4 		$45K Buy
+18,827
New +$76.7K ﹤0.01% 5217
2021
Q3 		– Sell
-10,483
Closed -$78K – 5512
2021
Q2 		$78K Buy
+10,483
New +$74.3K ﹤0.01% 4584

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's KLDO Position: Q1 2022 in Review

David Shaw sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q1 2022, closing a stake of 18,827 shares — an estimated $45K sold.

David Shaw first reported a position in KLDO in Q2 2021 and held it in 2 quarters. The position peaked at $78K in Q2 2021. 63 funds tracked by Wall St. Rank hold KLDO as of Q1 2022.

  • David Shaw reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • David Shaw sold 18,827 Kaleido Biosciences, Inc. Common Stock shares in Q1 2022, an estimated $45K.
  • David Shaw first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • David Shaw's Kaleido Biosciences, Inc. Common Stock position peaked at $78K in Q2 2021.
  • 63 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q1 2022.

Based on D.E. Shaw & Co's 13F filing for Q1 2022, filed 16 May 2022.